Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

DPC

DPC Holdings PLC

47.15

Jun 26 • 04:00PM ET +0.27 (0.58%)

Industrials Aerospace & Defense United Kingdom Large NYSE

Jun 25, 9:00 AMDoncasters (NYSE: DPC) prices its NYSE IPO at $33 per share, raising about $919 million and valuing the company at $4.72 billion ahead of first trading today.

Held by: FWD CGMM TMSL BCTK GSC NODE BRTR

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	451.75M	Perf Week	-
Market Cap	21.30B	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	22.00B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	0.58%
Book/sh	-0.52	P/C	645.45	EPS next 5Y	-	ROE	-	52W High	47.11 0.08%	Perf Year	-
Cash/sh	0.07	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	42.90 9.91%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	5.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.46	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.84	EPS Q/Q	-	SMA20	0.29%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	0.29%	Rel Volume	0.16	Prev Close	46.88
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	0.29%	Avg Volume	18.65M	Price	47.15
IPO	Jun 25, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	2,985,998	Change	0.58%

Jun-26-26 08:55AM	NYSE Content Update: Doncasters Shares Jump 42% in NYSE Trading Debut (PR Newswire)
Jun-25-26 04:10PM	J.F. Lehman & Company-Backed Doncasters Completes Successful IPO Listing (PR Newswire)
08:55AM	NYSE Content Update: Doncasters Raises $919 Million Ahead of NYSE Trading Debut (PR Newswire)

DPC Holdings Ltd. is an investment company, which engages in engine products which include complex precision cast components and nickel- and cobalt-based superalloys primarily serving the high growth of Aerospace and IGT end markets. It operates through the following segments: Engine Products-Europe, Engine Products-North America, and Turbo Wheels. The Engine Products-Europe segment refers to the sites Groton, Oxford, Springfield, Unipol Mexico, DPC New England, and Long Beach. The Engine Products-North America segment focuses on the engineered precision cast components and superalloys which are primarily used in the IGT end market with some elements of Aerospace. The Turbo Wheels segment manufactures turbocharger wheels and other precision components for commercial vehicles and passenger car turbo engines. The company was founded in November 2019 and is headquartered in Derby, the United Kingdom.

CEO & Executive DirectorMr. Michael Joseph Quinn

Chief Operating OfficerMr. Jason Mays

SolicitorMs. Helen Barrett-Hague LLB (Hons)

Chief People OfficerMs. Claire Davies

President of EuropeMr. Indy Rattu

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Nick	Director	Jun 26 '26	Buy	33.00	288,213	9,511,029	288,213	Jun 26 04:09 PM
Sanders Nick	Director	Jun 26 '26	Buy	33.00	6,030	198,990	149,780	Jun 26 04:09 PM
Quinn Michael (Mike) Joseph	CEO & Executive Director	Jun 26 '26	Buy	33.00	435,121	14,358,993	435,121	Jun 26 04:09 PM
Meixner Willibald	Director	Jun 26 '26	Buy	33.00	3,784	124,872	3,784	Jun 26 04:08 PM
Mays Jason	Chief Operating Officer	Jun 26 '26	Buy	33.00	85,973	2,837,109	93,456	Jun 26 04:08 PM
Deal Stanley A	Director	Jun 26 '26	Buy	33.00	16,360	539,880	16,360	Jun 26 04:07 PM
Danmola Taiwo K.	Director	Jun 26 '26	Buy	33.00	60,604	1,999,932	60,604	Jun 26 04:06 PM
Charles Dirkson R	Director	Jun 26 '26	Buy	33.00	903,448	29,813,784	903,448	Jun 26 04:06 PM
Charles Dirkson R	Director	Jun 26 '26	Buy	33.00	212,121	6,999,993	511,466	Jun 26 04:06 PM
Brooks Henry F	Director	Jun 26 '26	Buy	33.00	10,604	349,932	10,604	Jun 26 04:05 PM
Egan David John	CFO & Executive Director	Jun 26 '26	Buy	33.00	275,363	9,086,979	294,529	Jun 26 04:05 PM

FTH Faeth Therapeutics Inc daily Stock Chart

Peers: BCTX CLRB JSPR LGVN MRKR NXTC PLUR TPST TRAW VTGN

| Held by: VXF DFAS DFMC

Index	-	P/E	-	EPS (ttm)	-142.73	Insider Own	7.38%	Shs Outstand	1.34M	Perf Week	28.34%
Market Cap	589.56M	Forward P/E	-	EPS next Y	-6.53	Insider Trans	0.52%	Shs Float	-	Perf Month	37.36%
Enterprise Value	716.29M	PEG	-	EPS next Q	-3.54	Inst Own	-	Short Float	-	Perf Quarter	-14.92%
Income	-184.46M	P/S	-	EPS this Y	-691.77%	Inst Trans	2.86%	Short Ratio	14.68	Perf Half Y	148.32%
Sales	0.00M	P/B	-	EPS next Y	95.07%	ROA	-151.41%	Short Interest	0.80M	Perf YTD	114.34%
Book/sh	-102.43	P/C	2.91	EPS next 5Y	29.95%	ROE	-165.30%	52W High	36.76 -37.79%	Perf Year	172.91%
Cash/sh	7.87	P/FCF	-	EPS past 3/5Y	19.15% -4.83%	ROIC	-96.48%	52W Low	6.32 261.58%	Perf 3Y	-12.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	23.76% 19.52%	Perf 5Y	-89.56%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-518.34%	Oper. Margin	-	ATR (14)	3.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.39	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.00	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	14.39	EPS Q/Q	-2312.30%	SMA20	31.79%	Beta	-0.28	Target Price	54.40
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	6.25%	Rel Volume	2.66	Prev Close	24.67
Employees	29	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	36.18%	Avg Volume	54.39K	Price	22.87
IPO	Feb 04, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-21101.61% -	Trades		Volume	144,433	Change	-7.30%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-26	Initiated	Robert W. Baird	Outperform	$57
Jun-22-26	Initiated	H.C. Wainwright	Buy	$60
Jun-11-26	Initiated	BTIG Research	Buy	$55
May-29-26	Initiated	Cantor Fitzgerald	Overweight
May-22-26	Initiated	Citigroup	Buy	$55
Apr-20-26	Initiated	Leerink Partners	Outperform	$50
Jun-02-25	Resumed	H.C. Wainwright	Buy	$5
May-14-24	Initiated	Stephens	Overweight	$5
Jul-01-21	Downgrade	Berenberg	Buy → Hold	$12
Jun-29-21	Downgrade	Oppenheimer	Outperform → Perform	$30 → $14
Mar-01-21	Initiated	Piper Sandler	Overweight	$25
Mar-01-21	Initiated	Oppenheimer	Outperform	$36
Mar-01-21	Initiated	Citigroup	Buy	$30
Mar-01-21	Initiated	Berenberg	Buy	$27

Show Previous Ratings

Jun-15-26 08:10AM	Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer (Business Wire) +6.54%
Jun-04-26 04:00PM	Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -11.75%
May-15-26 07:30AM	Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
May-05-26 07:30AM	Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer (Business Wire)
Apr-09-26 07:30AM	Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
07:30AM	Loading…
Mar-30-26 07:30AM	Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update (Business Wire) -9.21%
Mar-17-26 06:00AM	Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-26 06:00AM	Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-18-26 12:09PM	Sensei Biotherapeutics Stock Soars 230% After Faeth Deal (Benzinga) +187.51%
08:00AM	Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement (Business Wire)
Nov-14-25 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.25%
Oct-31-25 02:06PM	Sensei to ditch its lead candidate and cut workforce amidst strategic review (Pharmaceutical Technology)
Oct-30-25 09:00AM	Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value (GlobeNewswire)
Oct-17-25 08:00AM	Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 (GlobeNewswire) -33.43%
Sep-23-25 07:30AM	Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 (GlobeNewswire)
08:00AM	Loading…
Sep-03-25 08:00AM	Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +10.57%
Aug-05-25 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-25 07:30AM	Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 (GlobeNewswire) +7.50%
Jun-13-25 07:30AM	Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -10.58%
May-06-25 07:30AM	Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress (GlobeNewswire) -5.29%
Apr-02-25 07:30AM	Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire) +6.09%
Mar-28-25 07:30AM	Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress (GlobeNewswire) +17.99%
Mar-27-25 04:05PM	Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors (GlobeNewswire)
Feb-06-25 12:00PM	What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock (Zacks)
Feb-04-25 07:30AM	Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-08-25 07:30AM	Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-27-24 04:05PM	Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -13.06%
Oct-29-24 07:30AM	Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences (GlobeNewswire)
Sep-04-24 04:05PM	Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference (GlobeNewswire)
07:30AM	Loading…
07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Aug-06-24 01:53PM	SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024 (InvestorPlace) +6.56%
07:30AM	Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-30-24 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -11.07%
May-24-24 08:27AM	Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? (InvestorPlace) -45.52%
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-23-24 05:10PM	Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 (GlobeNewswire) +6.62%
May-09-24 01:54PM	SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024 (InvestorPlace) -14.67%
07:30AM	Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-24-24 04:05PM	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-09-24 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference (GlobeNewswire) +6.28%
Apr-04-24 04:05PM	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment (GlobeNewswire)
Mar-22-24 07:30AM	Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium (GlobeNewswire) +11.43%
Mar-06-24 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences (GlobeNewswire)
Feb-28-24 07:30AM	Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +9.09%
Feb-07-24 07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) +6.12%
Jan-04-24 07:30AM	Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-07-23 08:09AM	Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results (GuruFocus.com) -7.15%
07:30AM	Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-23 04:05PM	Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire) -13.75% +9.42%
Nov-01-23 07:30AM	Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer (GlobeNewswire) +15.33%
Oct-25-23 09:05AM	Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire)
Oct-23-23 07:30AM	Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023 (GlobeNewswire)
Sep-27-23 07:30AM	Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron s Libtayo (GlobeNewswire) -10.17%
Sep-21-23 07:30AM	Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
Sep-13-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
Aug-30-23 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-03-23 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire)
Jun-13-23 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, A New Vista for Cancer Care: Exploring SNS-101s Potential as a Transformative Treatment Option for Patients with Solid Tumors (GlobeNewswire)
Jun-01-23 07:30AM	Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors (GlobeNewswire)
May-31-23 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 07:30AM	Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-20-23 07:30AM	Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Apr-18-23 04:05PM	Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Apr-13-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-30-23 07:30AM	Sensei Biotherapeutics to Participate in Cantor Fitzgeralds Future of Oncology Virtual Symposium (GlobeNewswire) +6.11%
Mar-28-23 07:30AM	Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-23-23 11:56AM	Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 07:30AM	Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Mar-14-23 04:35PM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) +9.92%
Mar-07-23 05:15PM	Sensei Biotherapeutics Adopts Stockholder Rights Agreement (GlobeNewswire) +6.49%
Mar-06-23 07:30AM	Sensei Biotherapeutics to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 07:30AM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire) -7.14%
Feb-16-23 07:30AM	Sensei Biotherapeutics to Participate in Citis 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-14-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire)
Feb-06-23 07:30AM	Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
Jan-05-23 07:30AM	Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors (GlobeNewswire)
Dec-08-22 01:10PM	Immunotherapy startup shutters Boston research site, lays off 17 (American City Business Journals)
10:40AM	Sensei Biotherapeutics Slashes Workforce, Closes R&D Site (Benzinga)
07:30AM	Sensei Biotherapeutics Provides Update on Strategic Priorities (GlobeNewswire)
Nov-22-22 07:30AM	Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-21-22 07:30AM	Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
06:00AM	Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate (GlobeNewswire)
Nov-10-22 09:00AM	Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +9.49%
Nov-08-22 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-22 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint (GlobeNewswire)
Nov-02-22 07:30AM	Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference (GlobeNewswire)
Oct-14-22 10:22AM	We're Keeping An Eye On Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Rate (Simply Wall St.)
Oct-05-22 08:05AM	Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-30-22 04:05PM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) +7.10%
Sep-21-22 04:05PM	Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) -5.32%
Aug-31-22 07:30AM	Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody (GlobeNewswire)
Aug-23-22 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-22 07:02AM	One Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insider upped their stake by 13% in the previous year (Simply Wall St.)
Aug-09-22 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -5.37%
Jun-01-22 07:30AM	Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer (GlobeNewswire)
May-25-22 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference (GlobeNewswire) -6.32%
May-10-22 07:30AM	Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +9.80%

Faeth Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

CEOAnand Parikh

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STEPHENSON BRIAN C	Chief Financial Officer	Jun 24 '26	Buy	26.13	9,391	245,360	26,804	Jun 26 07:40 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 26 '26	Buy	24.95	6,250	155,908	33,054	Jun 26 07:40 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 23 '26	Buy	24.36	9,230	224,806	17,413	Jun 24 06:58 PM
STEPHENSON BRIAN C	Chief Financial Officer	Jun 22 '26	Buy	22.13	8,183	181,115	8,183	Jun 24 06:58 PM
Parikh Anand Kiran	President and CEO	Jun 22 '26	Option Exercise	1.16	53,465	62,019	817,699	Jun 24 06:55 PM
Parikh Anand Kiran	President and CEO	Jun 22 '26	Buy	19.76	2,806	55,447	764,234	Jun 24 06:55 PM
Cambrian BioPharma Inc	10% Owner	Jun 01 '26	Sale	20.02	25,000	500,543	130,142	Jun 01 05:21 PM
Peyer James	10% Owner	Jun 01 '26	Sale	20.02	25,000	500,543	130,142	Jun 01 05:20 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 02 '26	Buy	35.01	2,003	70,133	144,974	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 07 '26	Buy	33.38	1,108	36,985	133,986	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 06 '26	Buy	31.02	1,104	34,246	141,029	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 07 '26	Sale	31.01	8,151	252,775	133,986	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 02 '26	Sale	32.12	7,666	246,239	144,974	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 06 '26	Sale	31.06	1,259	39,100	141,029	May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 01 '26	Buy	34.49	6,175	212,979	147,731	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 31 '26	Buy	28.16	6,005	169,121	146,657	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 31 '26	Sale	25.49	1,591	40,553	146,657	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Apr 01 '26	Sale	31.65	1,150	36,396	147,731	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 27 '26	Buy	26.61	15,321	407,717	142,360	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 30 '26	Buy	25.86	9,533	246,495	145,678	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 26 '26	Buy	28.62	5,731	164,045	131,370	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 26 '26	Sale	28.12	1,857	52,220	131,370	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 30 '26	Sale	26.61	888	23,632	145,678	May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC	10% Owner	Mar 27 '26	Sale	26.81	505	13,538	142,360	May 15 04:22 PM
Cambrian BioPharma Inc	10% Owner	Apr 29 '26	Proposed Sale	31.95	155,142	4,956,786		Apr 29 03:26 PM
Celebi John	Former Officer	Feb 24 '26	Proposed Sale	34.49	3,374	116,356		Feb 24 04:11 PM
Peyer James	Fomer Director	Feb 18 '26	Proposed Sale	27.13	950	25,769		Feb 18 01:22 PM
RINGO WILLIAM R	Former Director	Jan 27 '26	Proposed Sale	9.83	1,169	11,486		Jan 27 05:33 PM
Cambrian BioPharma Inc	10% Owner	Dec 09 '25	Option Exercise	6.40	395	2,528	155,983	Dec 10 04:56 PM
Cambrian BioPharma Inc	10% Owner	Dec 09 '25	Sale	8.25	6,612	54,575	155,142	Dec 10 04:56 PM
Peyer James	10% Owner	Dec 09 '25	Option Exercise	6.40	395	2,528	155,983	Dec 10 04:52 PM
Peyer James	10% Owner	Dec 09 '25	Sale	7.96	3,507	27,903	155,142	Dec 10 04:52 PM
Peyer James	10% Owner	Dec 08 '25	Sale	8.59	3,105	26,672	158,254	Dec 10 04:52 PM
Peyer James	Former Director	Dec 09 '25	Proposed Sale	7.97	841	6,707		Dec 09 12:20 PM
Cambrian BioPharma Inc	10% Owner	Dec 05 '25	Sale	11.50	16,295	187,390	161,359	Dec 08 04:39 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Sale	9.06	5,000	45,300	177,654	Dec 08 04:39 PM
Peyer James	10% Owner	Dec 05 '25	Sale	11.50	16,295	187,390	161,359	Dec 08 04:36 PM
Peyer James	10% Owner	Dec 04 '25	Sale	9.06	5,000	45,300	177,654	Dec 08 04:36 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Proposed Sale	8.71	5,844	50,901		Dec 04 04:18 PM
Cambrian BioPharma Inc	10% Owner	Dec 04 '25	Proposed Sale	8.71	21,222	184,843		Dec 04 03:41 PM

Peers: DOYU FLX GLBE HUYA ZH DIBS CARG BILI BIDU RUM

| Held by: AVDV DFEM DFAE EWX PGJ APIE DFAX DFEV DFSE AVDS

Index	-	P/E	-	EPS (ttm)	-0.45	Insider Own	0.72%	Shs Outstand	53.67M	Perf Week	-0.72%
Market Cap	148.67M	Forward P/E	4.27	EPS next Y	0.65	Insider Trans	132.52%	Shs Float	53.67M	Perf Month	9.49%
Enterprise Value	322.82M	PEG	-	EPS next Q	-	Inst Own	23.88%	Short Float	0.87%	Perf Quarter	27.06%
Income	-26.09M	P/S	0.10	EPS this Y	122.22%	Inst Trans	1.74%	Short Ratio	1.27	Perf Half Y	1.84%
Sales	1.45B	P/B	0.31	EPS next Y	57.51%	ROA	-1.89%	Short Interest	0.47M	Perf YTD	4.14%
Book/sh	9.03	P/C	0.35	EPS next 5Y	-	ROE	-4.95%	52W High	4.88 -43.24%	Perf Year	7.57%
Cash/sh	7.95	P/FCF	-	EPS past 3/5Y	28.42% -	ROIC	-4.42%	52W Low	2.07 33.82%	Perf 3Y	-28.79%
Dividend Est.	-	EV/EBITDA	21.11	Sales past 3/5Y	3.51% 1.53%	Gross Margin	73.15%	Volatility	6.65% 4.61%	Perf 5Y	-92.36%
Dividend TTM	-	EV/Sales	0.22	EPS Y/Y TTM	-5.82%	Oper. Margin	0.76%	ATR (14)	0.13	Perf 10Y	-56.65%
Dividend Ex-Date	-	Quick Ratio	1.49	Sales Y/Y TTM	9.72%	Profit Margin	-1.80%	RSI (14)	54.34	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	1.82	EPS Q/Q	87.67%	SMA20	2.20%	Beta	0.47	Target Price	4.23
Payout	-	Debt/Eq	0.63	Sales Q/Q	21.21%	SMA50	1.68%	Rel Volume	0.44	Prev Close	2.76
Employees	6762	LT Debt/Eq	0.13	Earnings	May 20 BMO	SMA200	-5.38%	Avg Volume	369.88K	Price	2.77
IPO	May 21, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	- 4.25%	Trades		Volume	163,951	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-30-24	Downgrade	CLSA	Outperform → Hold
Mar-26-24	Downgrade	China Renaissance	Buy → Hold
Feb-08-24	Upgrade	Daiwa Securities	Outperform → Buy
Feb-27-23	Upgrade	CLSA	Underperform → Outperform	$4.40 → $7
Jan-30-23	Initiated	JP Morgan	Overweight
Jan-11-23	Upgrade	JP Morgan	Neutral → Overweight	$9 → $10
May-16-22	Upgrade	JP Morgan	Underweight → Neutral	$5 → $8
Mar-14-22	Downgrade	JP Morgan	Overweight → Underweight	$5
Mar-11-22	Upgrade	Credit Suisse	Underperform → Neutral	$8.30
Dec-02-21	Downgrade	CLSA	Buy → Outperform
Aug-20-21	Downgrade	Daiwa Securities	Buy → Neutral	$42 → $20
Jul-23-21	Downgrade	Credit Suisse	Outperform → Underperform
Jun-08-21	Resumed	JP Morgan	Overweight	$45
May-19-21	Upgrade	Credit Suisse	Neutral → Outperform	$41
Jan-25-21	Upgrade	CLSA	Outperform → Buy	$42
Nov-24-20	Downgrade	Credit Suisse	Outperform → Neutral
Jun-03-20	Upgrade	Credit Suisse	Neutral → Outperform	$36
Mar-31-20	Downgrade	BofA/Merrill	Buy → Neutral
Nov-22-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-22-19	Downgrade	CLSA	Buy → Outperform

Show Previous Ratings

Jun-16-26 07:22PM	Baozun Announces Results of Annual General Meeting of Shareholders (PR Newswire)
May-20-26 03:01PM	Baozun Inc (BZUN) Q1 2026 Earnings Call Highlights: Revenue Surge and Profit Turnaround (GuruFocus.com)
06:00AM	Baozun Announces First Quarter 2026 Unaudited Financial Results (PR Newswire)
May-15-26 06:00AM	Baozun Schedules Annual General Meeting of Shareholders (PR Newswire) -8.89%
May-08-26 06:00AM	Baozun to Announce First Quarter 2026 Unaudited Financial Results on May 20, 2026 (PR Newswire)
07:42AM	Loading…
Apr-23-26 07:42AM	Baozun Releases 2025 Annual Sustainability Report (PR Newswire)
06:50AM	Baozun Files Annual Reports for Fiscal Year 2025 (PR Newswire)
06:00AM	Baozun Releases 2025 Chairman Letter (PR Newswire)
Mar-26-26 02:39PM	Gap Plans 50 China Stores After First Quarterly Breakeven (GuruFocus.com) -12.10%
Mar-25-26 03:01PM	Baozun Inc (BZUN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Profitability ... (GuruFocus.com) +16.43%
06:15AM	Baozun Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results (PR Newswire)
Mar-11-26 06:00AM	Baozun to Announce Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results on March 25, 2026 (PR Newswire)
Nov-25-25 02:00PM	Baozun Inc (BZUN) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic Focus on ... (GuruFocus.com) -5.82%
05:00AM	Baozun Announces Third Quarter 2025 Unaudited Financial Results (PR Newswire)
Nov-11-25 05:00AM	Baozun to Announce Third Quarter 2025 Unaudited Financial Results on November 25, 2025 (PR Newswire)
01:32PM	Loading…
Sep-22-25 01:32PM	Accenture Pre-Q4 Earnings: Is the Stock a Portfolio Must-Have? (Zacks)
Aug-29-25 03:04AM	Baozun Inc (BZUN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion (GuruFocus.com) +6.27%
Aug-28-25 06:00AM	Baozun Announces Second Quarter 2025 Unaudited Financial Results (PR Newswire) +12.72%
Aug-14-25 06:00AM	Baozun to Announce Second Quarter 2025 Unaudited Financial Results on August 28, 2025 (PR Newswire)
Jul-21-25 09:40AM	Is Baozun (BZUN) Stock Outpacing Its Computer and Technology Peers This Year? (Zacks)
Jun-18-25 06:00AM	Baozun Announces Results of Annual General Meeting of Shareholders (PR Newswire)
May-22-25 03:03AM	Baozun Inc (BZUN) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions ... (GuruFocus.com)
May-21-25 06:00AM	Baozun Announces First Quarter 2025 Unaudited Financial Results (PR Newswire)
May-16-25 06:00AM	Baozun Schedules Annual General Meeting of Shareholders (PR Newswire)
May-07-25 06:00AM	Baozun to Announce First Quarter 2025 Unaudited Financial Results on May 21, 2025 (PR Newswire) +6.84%
Apr-23-25 07:17AM	Baozun Releases 2024 Sustainability Report (PR Newswire)
06:38AM	Baozun Files Annual Reports for Fiscal Year 2024 (PR Newswire)
06:00AM	Baozun Releases 2024 Chairman Letter (PR Newswire)
Apr-18-25 11:35AM	Is Baozun Inc. (BZUN) the Best Internet Retail Stock to Buy According to Analysts? (Insider Monkey)
Mar-30-25 08:00AM	Baozun: Decent Buy Opportunity After The Correction (Seeking Alpha)
03:01AM	Loading…
Mar-21-25 03:01AM	Baozun Inc (BZUN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions (GuruFocus.com)
Mar-20-25 12:30PM	Baozun (BZUN) Q4 2024 Earnings Call Transcript (Motley Fool) -12.71%
09:01AM	Baozun Inc. (BZUN) Q4 2024 Earnings Call Transcript (SeekingAlpha)
06:00AM	Baozun Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results (PR Newswire)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha)
Mar-06-25 05:00AM	Baozun to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 (PR Newswire)
Feb-27-25 10:32AM	Why Baozun Inc. (BZUN) Is Skyrocketing So Far In 2025 (Insider Monkey) -5.52%
Feb-10-25 07:56PM	Why Baozun Inc. (BZUN) Is Skyrocketing (Insider Monkey)
Nov-22-24 02:02AM	Baozun Inc (BZUN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Profitability ... (GuruFocus.com)
Nov-21-24 11:00AM	Baozun (BZUN) Q3 2024 Earnings Call Transcript (Motley Fool) -8.11%
05:00AM	Baozun Announces Third Quarter 2024 Unaudited Financial Results (PR Newswire)
Nov-07-24 05:00AM	Baozun to Announce Third Quarter Financial Results of 2024 Unaudited Financial Results on November 21, 2024 (PR Newswire)
Oct-17-24 06:28AM	Baozun Inc. Announces Strategic Share Repurchase (TipRanks)
Oct-16-24 06:50AM	Baozun Inc. Announces Strategic Share Repurchase (TipRanks)
Oct-10-24 06:29AM	Baozun Announces Share Repurchase Update (TipRanks)
Oct-09-24 07:27AM	Baozun Announces Recent Share Repurchase (TipRanks)
Oct-08-24 07:17AM	Baozun Announces Recent Share Repurchase (TipRanks) -10.22%
Oct-05-24 06:31AM	Baozun Announces Share Repurchase Update (TipRanks)
Aug-28-24 02:30PM	Baozun (BZUN) Q2 2024 Earnings Call Transcript (Motley Fool)
06:28AM	Baozun Announces Second Quarter 2024 Unaudited Financial Results (PR Newswire)
Aug-14-24 06:00AM	Baozun to Announce Second Quarter and Half-Year Interim Financial Results of 2024 Unaudited Financial Results on August 28, 2024 (PR Newswire)
Jun-12-24 07:26AM	Baozun Announces Results of Annual General Meeting of Shareholders (PR Newswire)
May-31-24 05:30AM	Alibaba sells stake in e-commerce branding services firm Baozun for US$21.8 million as part of corporate restructuring (South China Morning Post)
May-29-24 08:03AM	Baozun Inc. (NASDAQ:BZUN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-28-24 01:00PM	Baozun (BZUN) Q1 2024 Earnings Call Transcript (Motley Fool)
10:52AM	BZUN Stock Earnings: Baozun Beats Revenue for Q1 2024 (InvestorPlace)
06:00AM	Baozun Announces First Quarter 2024 Unaudited Financial Results (PR Newswire)
May-14-24 06:00AM	Baozun to Announce First Quarter 2024 Unaudited Financial Results on May 28, 2024 (PR Newswire)
May-10-24 06:00AM	Baozun Schedules Annual General Meeting of Shareholders (PR Newswire)
Apr-19-24 07:13AM	Baozun Releases 2023 Sustainability Report (PR Newswire)
06:34AM	Baozun Strengthens Leadership Team (PR Newswire)
06:26AM	Baozun Files Annual Reports for Fiscal Year 2023 (PR Newswire)
06:00AM	Baozun Releases 2023 Chairman Letter (PR Newswire)
Mar-26-24 08:51AM	Baozun Inc. (NASDAQ:BZUN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 12:45PM	Baozun (BZUN) Q4 2023 Earnings Call Transcript (Motley Fool) -16.67%
10:53AM	BZUN Stock Earnings: Baozun Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:00AM	Baozun Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results (PR Newswire)
Mar-07-24 04:32PM	7 Under-$10 Stocks That Will Be Worth $100 (or More!) by 2026 (InvestorPlace)
05:00AM	Baozun to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results on March 21, 2024 (PR Newswire)
Feb-16-24 03:15AM	20 Fastest Growing E-Commerce Companies in 2024 (Insider Monkey)
Jan-24-24 06:00AM	Baozun Announces US$20 million Share Repurchase Program (PR Newswire) +17.33%
Nov-24-23 08:44AM	Baozun Inc. (NASDAQ:BZUN) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.46%
Nov-22-23 10:45AM	Baozun (BZUN) Q3 2023 Earnings Call Transcript (Motley Fool) -10.12%
05:00AM	Baozun Announces Third Quarter 2023 Unaudited Financial Results (PR Newswire)
Nov-08-23 05:00AM	Baozun to Announce Third Quarter Financial Results of 2023 Unaudited Financial Results on November 22, 2023 (PR Newswire)
Oct-05-23 05:17PM	Ray Dalio on Potential US-China War and Rise of China (Insider Monkey) +5.72%
Aug-29-23 08:12AM	Baozun Inc. (NASDAQ:BZUN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-28-23 03:39PM	Why Baozun Stock Popped Today (Motley Fool) +12.47%
01:00PM	Baozun (BZUN) Q2 2023 Earnings Call Transcript (Motley Fool)
12:37PM	Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories (Benzinga)
06:00AM	Baozun Announces Second Quarter 2023 Unaudited Financial Results (PR Newswire)
Aug-14-23 06:00AM	Baozun to Announce Second Quarter and Half-Year Interim Financial Results of 2023 Unaudited Financial Results on August 28, 2023 (PR Newswire)
Jul-14-23 10:22AM	Positive week for Baozun Inc. (NASDAQ:BZUN) institutional investors who lost 52% over the past year (Simply Wall St.)
Jun-27-23 04:18PM	Why Alibaba, Bilibili, and Baozun Rose Today (Motley Fool)
Jun-15-23 08:20AM	Baozun Announces Results of Annual General Meeting of Shareholders (PR Newswire)
Jun-02-23 11:54AM	Why Shares of Alibaba, Dingdong, and Baozun Are Rising Today (Motley Fool)
May-25-23 02:47PM	Why Baozun Stock Was Falling Today (Motley Fool) -9.65%
01:30PM	Baozun (BZUN) Q1 2023 Earnings Call Transcript (Motley Fool)
06:00AM	Baozun Announces First Quarter 2023 Unaudited Financial Results (PR Newswire)
May-15-23 06:00AM	Baozun Schedules Annual General Meeting of Shareholders (GlobeNewswire) +7.57%
May-12-23 06:00AM	Baozun to Announce First Quarter 2023 Unaudited Financial Results on May 25, 2023 (GlobeNewswire) -5.42%
Apr-29-23 08:34AM	Baozun (NASDAQ:BZUN) investors are sitting on a loss of 90% if they invested five years ago (Simply Wall St.)
Apr-25-23 06:34AM	Baozun Releases 2022 Sustainability Report (GlobeNewswire)
06:27AM	Baozun Files Annual Report on Form 20-F for Fiscal Year 2022 (GlobeNewswire)
06:19AM	Baozun Releases 2022 Chairman Letter (GlobeNewswire)
Mar-25-23 08:41AM	Baozun Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-24-23 07:15AM	Baozun Inc. (NASDAQ:BZUN) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.26%
06:42AM	Baozun (NASDAQ:BZUN) Might Be Having Difficulty Using Its Capital Effectively (Simply Wall St.)
Mar-22-23 12:18PM	Why Baozun Stock Was Sinking Today (Motley Fool) -9.41%
10:08AM	Baozun Registers 20% Topline Decline In Q4 Weighed Down By GMV Weakness; Updates On Newer Business Lines (Benzinga)

Baozun, Inc. is a holding company, which engages in the provision of brand electronic commerce (e-commerce) services and solutions. Its services include apparel and accessories, appliances, electronics, home and furnishings, food and health products, beauty and cosmetics, fast moving consumer goods, and mother and baby products, and insurance and automobiles. The firm operates through the E-Commerce and Brand Management segments. The company was founded by Wen Bin Qiu, Jun Hua Wu, and Qing Yu Zhang in August 2007 and is headquartered in Shanghai, China.

Co-FounderMr. Wenbin Qiu

Co-FounderMr. Junhua Wu

Chief Financial OfficerMs. Yanjie Zhu

Joint Company Secretary and Senior Director of Corporate Development & Investor RelationsMs. Wendy Shu Sun

Senior Vice PresidentMr. Yuen Lung Kwok

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wu Junhua	Chief Strategy Officer	Jun 24 '26	Buy	2.85	29,000	82,650	253,770	Jun 26 07:39 AM
Qiu Wenbin	Chief Executive Officer	Jun 22 '26	Buy	2.81	10,000	28,100	1,623,872	Jun 24 07:24 AM
Qiu Wenbin	Chief Executive Officer	Jun 17 '26	Buy	2.83	10,000	28,300	1,603,872	Jun 22 06:33 AM
Qiu Wenbin	Chief Executive Officer	Jun 18 '26	Buy	2.77	10,000	27,700	1,613,872	Jun 22 06:33 AM
Wu Junhua	Chief Strategy Officer	Jun 17 '26	Buy	2.84	18,500	52,540	224,770	Jun 22 06:27 AM
Qiu Wenbin	Chief Executive Officer	Jun 15 '26	Buy	2.79	10,000	27,900	1,583,872	Jun 17 07:49 AM
Qiu Wenbin	Chief Executive Officer	Jun 16 '26	Buy	2.72	10,000	27,200	1,593,872	Jun 17 07:49 AM
Qiu Wenbin	Chief Executive Officer	Jun 12 '26	Buy	2.72	10,000	27,200	1,573,872	Jun 15 06:21 AM
Qiu Wenbin	Chief Executive Officer	Jun 11 '26	Buy	2.67	10,000	26,700	1,563,872	Jun 15 06:21 AM
Wu Junhua	Chief Strategy Officer	Jun 11 '26	Buy	2.69	18,000	48,420	206,270	Jun 15 06:19 AM
Qiu Wenbin	Chief Executive Officer	Jun 09 '26	Buy	2.72	10,000	27,200	1,543,872	Jun 11 06:15 AM
Qiu Wenbin	Chief Executive Officer	Jun 10 '26	Buy	2.64	10,000	26,400	1,553,872	Jun 11 06:15 AM
Qiu Wenbin	Chief Executive Officer	Jun 08 '26	Buy	2.77	10,000	27,700	1,533,872	Jun 09 06:20 AM
Qiu Wenbin	Chief Executive Officer	Jun 05 '26	Buy	2.65	10,000	26,500	1,523,872	Jun 09 06:20 AM
Qiu Wenbin	Chief Executive Officer	Jun 04 '26	Buy	2.67	10,000	26,700	1,513,872	Jun 05 06:16 AM
Qiu Wenbin	Chief Executive Officer	Jun 03 '26	Buy	2.63	10,000	26,300	1,503,872	Jun 05 06:16 AM
Wu Junhua	Chief Strategy Officer	Jun 01 '26	Buy	2.70	20,000	54,000	188,270	Jun 03 06:30 AM
Qiu Wenbin	Chief Executive Officer	Jun 01 '26	Buy	2.73	10,000	27,300	1,483,872	Jun 03 06:26 AM
Qiu Wenbin	Chief Executive Officer	Jun 02 '26	Buy	2.69	10,000	26,900	1,493,872	Jun 03 06:26 AM
Wu Junhua	Chief Strategy Officer	May 28 '26	Buy	2.56	19,500	49,920	168,270	Jun 01 07:53 AM
Qiu Wenbin	Chief Executive Officer	May 29 '26	Buy	2.57	10,000	25,700	1,473,872	Jun 01 07:46 AM
Qiu Wenbin	Chief Executive Officer	May 28 '26	Buy	2.56	10,000	25,600	1,463,872	Jun 01 07:46 AM
Qiu Wenbin	Chief Executive Officer	May 27 '26	Buy	2.58	10,000	25,800	1,453,872	May 28 06:48 AM
Qiu Wenbin	Chief Executive Officer	May 26 '26	Buy	2.55	10,000	25,500	1,443,872	May 28 06:48 AM
Wu Junhua	Chief Strategy Officer	May 26 '26	Buy	2.55	10,000	25,500	148,770	May 28 06:45 AM
Qiu Wenbin	Chief Executive Officer	Apr 17 '26	Buy	3.14	16,000	50,240	1,433,872	Apr 21 06:15 AM
Qiu Wenbin	Chief Executive Officer	Apr 16 '26	Buy	2.84	17,500	49,700	1,417,872	Apr 17 07:33 AM
Qiu Wenbin	Chief Executive Officer	Apr 15 '26	Buy	2.71	11,000	29,810	1,400,372	Apr 17 07:33 AM
Qiu Wenbin	Chief Executive Officer	Apr 14 '26	Buy	2.63	11,500	30,245	1,389,372	Apr 15 06:30 AM
Qiu Wenbin	Chief Executive Officer	Apr 13 '26	Buy	2.48	12,100	30,008	1,377,872	Apr 15 06:30 AM
Wu Junhua	Chief Strategy Officer	Apr 13 '26	Buy	2.49	11,084	27,599	138,770	Apr 14 07:47 AM
Wu Junhua	Chief Strategy Officer	Apr 10 '26	Buy	2.40	5,372	12,893	127,686	Apr 14 07:47 AM
Qiu Wenbin	Chief Executive Officer	Apr 10 '26	Buy	2.43	12,400	30,132	1,365,772	Apr 13 06:19 AM
Qiu Wenbin	Chief Executive Officer	Apr 09 '26	Buy	2.58	11,650	30,057	1,353,372	Apr 13 06:19 AM
Wu Junhua	Chief Strategy Officer	Apr 08 '26	Buy	2.54	30,886	78,450	122,314	Apr 10 06:18 AM
Qiu Wenbin	Chief Executive Officer	Apr 07 '26	Buy	2.51	12,000	30,120	1,330,122	Apr 09 06:31 AM
Qiu Wenbin	Chief Executive Officer	Apr 08 '26	Buy	2.58	11,600	29,928	1,341,722	Apr 09 06:31 AM
Wu Junhua	Chief Strategy Officer	Apr 02 '26	Buy	2.47	30,000	74,019	91,428	Apr 06 08:47 AM
Wu Junhua	Chief Strategy Officer	Mar 31 '26	Buy	2.40	14,000	33,597	61,428	Apr 01 09:52 PM

CTGO Contango Silver & Gold Inc daily Stock Chart

Peers: FSM HSLV NEWP CDE PAAS VZLA EXK AYA SVM HL

Index	RUT	P/E	-	EPS (ttm)	-1.63	Insider Own	15.16%	Shs Outstand	30.51M	Perf Week	-7.30%
Market Cap	484.34M	Forward P/E	3.65	EPS next Y	4.31	Insider Trans	-1.06%	Shs Float	26.11M	Perf Month	-20.82%
Enterprise Value	419.75M	PEG	-	EPS next Q	0.68	Inst Own	35.43%	Short Float	7.04%	Perf Quarter	-5.69%
Income	-28.44M	P/S	-	EPS this Y	160.27%	Inst Trans	13.02%	Short Ratio	3.07	Perf Half Y	-45.76%
Sales	0.00M	P/B	1.49	EPS next Y	155.41%	ROA	-8.84%	Short Interest	1.84M	Perf YTD	-40.40%
Book/sh	10.54	P/C	4.96	EPS next 5Y	-	ROE	-18.90%	52W High	34.38 -54.22%	Perf Year	-24.83%
Cash/sh	3.17	P/FCF	-	EPS past 3/5Y	20.70% -	ROIC	-8.30%	52W Low	14.50 8.55%	Perf 3Y	-35.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.15% 6.27%	Perf 5Y	-28.45%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	56.60%	Oper. Margin	-	ATR (14)	1.19	Perf 10Y	78.86%
Dividend Ex-Date	-	Quick Ratio	1.27	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.68	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.27	EPS Q/Q	55.77%	SMA20	-6.63%	Beta	0.02	Target Price	38.33
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-23.46%	Rel Volume	3.03	Prev Close	14.92
Employees	15	LT Debt/Eq	0.07	Earnings	May 14 BMO	SMA200	-34.08%	Avg Volume	598.65K	Price	15.74
IPO	Dec 20, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	-58.07% -	Trades		Volume	1,813,053	Change	5.50%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Canaccord Genuity	Buy	$32
Sep-14-23	Initiated	Maxim Group	Buy	$36

Jun-23-26 08:00AM	Contango Silver & Gold Provides Project Updates (PR Newswire)
Jun-18-26 04:45PM	Contango Announces Results of the 2026 Virtual Annual Meeting of Stockholders (PR Newswire) -5.95%
Jun-16-26 08:00AM	Contango Silver & Gold Intersects 972.10 g/t Gold at Lucky Shot and Continues Underground Exploration Development Program (PR Newswire)
Jun-12-26 09:53AM	Contango Silver & Gold Inc. (CTGO) Opens the Market (TMX Newsfile)
May-26-26 08:00AM	Contango Commences 40,000-meter 2026 Drill Program at the Kitsault Valley Silver-Gold Project (PR Newswire)
09:00PM	Loading…
May-25-26 09:00PM	Contango Silver & Gold Inc (CTGO) Q1 2026 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
May-15-26 12:16PM	Contango targets 200,000-ounce gold output by 2030 as North American pipeline grows (Proactive) -9.19%
May-14-26 07:55AM	Contango Announces Results for the Quarter Ended March 31, 2026 (PR Newswire) -6.26%
May-07-26 11:00AM	Lake Victoria Gold Mobilizes Rigs for Sterilization Drilling at Imwelo as Project Advances Toward Production (PR Newswire)
May-05-26 08:00AM	Contango Enhances Economics with High-Grade Drill Results and Strategic Acquisition of the Lucky Shot Lease and Royalty (PR Newswire)
Apr-24-26 03:00PM	BTV Spotlights: Alkane Resources, Mineros S.A., Osisko Development, Contango Silver & Gold, Lion Copper and Gold, North American Iron, & Elemental Royalty (TMX Newsfile)
08:55AM	NYSE Content Update: AI Company Vast Data Announces $30 Billion Valuation (PR Newswire)
Apr-22-26 08:00AM	Contango Announces $9.0 Million Cash Distribution from the Peak Gold JV and Update on 2026 Exploration Plans (PR Newswire) +5.54%
Apr-13-26 08:00AM	Contango Announces Listing on Toronto Stock Exchange (PR Newswire)
Apr-01-26 06:08AM	VIDEO - BTV Visits Equinox Gold, Mineros, Elemental Royalty, 5E Advanced Materials, Alkane Resources, Contango Silver & Gold, and Osisko Development (TMX Newsfile)
08:00AM	Loading…
Mar-26-26 08:00AM	Contango Completes Merger with Dolly Varden (PR Newswire) -6.66%
Mar-20-26 09:00AM	BTV Spotlights: Picard Medical, Contango, GMG, 5E Advanced, Klondike Gold, Nevada Organic, Nine Mile, FireFox, & Intrepid Metals (TMX Newsfile)
Mar-18-26 09:01PM	Contango Ore Inc (CTGO) Q4 2025 Earnings Call Highlights: Strategic Moves and Financial Growth ... (GuruFocus.com) -7.67% -10.50%
Mar-17-26 05:10PM	Dolly Varden Receives Shareholder Approval for Merger with Contango Ore (TMX Newsfile) -6.51%
05:00PM	Contango Stockholders Overwhelmingly Approve Merger with Dolly Varden (PR Newswire)
Mar-16-26 07:00AM	Contango Announces 2025 Year End Financials and Provides 2026 and 2027 Production Guidance (PR Newswire)
Mar-09-26 08:00AM	Independent Proxy Advisory Firms, Including ISS, Recommend Dolly Varden Shareholders Vote "FOR" Proposed Plan of Arrangement with Contango Ore, Inc.; Shareholders Reminded to Vote (TMX Newsfile)
08:00AM	INDEPENDENT PROXY ADVISORY FIRMS RECOMMEND CONTANGO ORE, INC. STOCKHOLDERS VOTE "FOR" PROPOSED ARRANGEMENT WITH DOLLY VARDEN SILVER CORPORATION (PR Newswire)
Mar-03-26 01:47AM	Contango Ore, Inc. (CTGO) Advances Alaska Projects and Strengthens Balance Sheet (Insider Monkey)
Feb-25-26 12:00PM	BTV Showcases Contango Ore, Critical Elements Lithium, Dryden Gold, FireFox Gold, Kirkland Lake, Klondike Gold, and Selkirk Copper (Newsfile)
08:00AM	Contango Ore Intersects 60.22 g/t Gold over 5.92 meters, including 294.77 g/t Gold over 1.16 meters from Underground Drilling Program at the Lucky Shot Project, Alaska, USA (PR Newswire)
Feb-23-26 08:00AM	CONTANGO ORE, INC. ANNOUNCES FILING AND MAILING OF SPECIAL MEETING PROXY STATEMENT IN CONNECTION WITH THE PROPOSED PLAN OF ARRANGEMENT WITH DOLLY VARDEN (PR Newswire)
Feb-17-26 08:00AM	Contango Provides Corporate Update on Johnson Tract Critical Metals Project, Manh Choh Mine and Hedge Settlements (PR Newswire) -7.46%
Feb-16-26 11:49AM	Are CTGO, FONR, CWAN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Feb-13-26 04:30PM	Dolly Varden Silver Announces Filing of Special Meeting Circular and Receipt of Interim Order in Respect of Previously Announced Arrangement with Contango ORE (TMX Newsfile) -7.46%
10:07AM	Loading…
Feb-12-26 10:07AM	Contango Webinar Scheduled for Thursday February 12, 2026 (PR Newswire) -9.06%
10:05AM	Contango Ore Closes $50 Million Underwritten Offering of Common Stock and Pre-funded Warrants (PR Newswire)
Feb-11-26 08:36AM	Contango Ore Announces $50 Million Underwritten Offering of Common Stock and Pre-funded Warrants (PR Newswire)
Jan-23-26 11:01AM	Halper Sadeh LLC Encourages DHIL, GBIO, CTGO Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-13-26 01:52AM	Halper Sadeh LLC Encourages CTGO, GBIO, CDE Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-23-25 06:39PM	VIDEO - Dolly Varden's Next Chapter as a North American Mid-Tier Precious Metals Company (TMX Newsfile)
Dec-15-25 03:29PM	Halper Sadeh LLC Encourages DHIL, CTGO, SNCR, CFLT Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-09-25 10:09AM	Gold Holds $4,200 Level As M&A Surge And High-Grade Discoveries Ignite Sector Valuation Reset (PR Newswire) +6.15%
Dec-08-25 07:30AM	Contango ORE and Dolly Varden Silver Announce Merger to Create a New North American High-Grade, Mid-Tier Silver & Gold Producer and Developer (PR Newswire)
Dec-02-25 04:30PM	Contango Announces Acceptance of the Johnson Tract Critical Metals Project to the Covered Projects FAST-41 Program (PR Newswire) +6.27%
Nov-24-25 08:02PM	Contango Ore Inc (CTGO) Q3 2025 Earnings Call Highlights: Record Operating Income and Strategic ... (GuruFocus.com) +5.44%
Nov-19-25 05:00PM	Contango Announces Start of Lucky Shot Underground Drill Program to Complete Feasibility Study (PR Newswire)
Nov-18-25 08:55AM	Is HBM's Copper World JV With Mitsubishi a Potential Breakthrough? (Zacks)
Nov-13-25 05:00PM	Contango Announces Record High $25 Million in Income from Operations and Cash Position of $107 Million for the Quarter Ended September 30, 2025 (PR Newswire) -5.52%
Nov-05-25 09:40AM	Are Basic Materials Stocks Lagging Buenaventura Mining (BVN) This Year? (Zacks)
Oct-21-25 11:33AM	BASF & Xiaomi Team Up to Co-Create 100 Car Colors, Enhance Aesthetics (Zacks) -8.88%
09:03AM	PPG Launches Next-Generation ENVIROCRON Powder Coating (Zacks)
Oct-20-25 09:55AM	Wall Street Analysts Think Contango ORE, Inc. (CTGO) Could Surge 38.78%: Read This Before Placing a Bet (Zacks)
09:40AM	Is Buenaventura Mining (BVN) Stock Outpacing Its Basic Materials Peers This Year? (Zacks)
Oct-07-25 10:13AM	CF Industries Ships Its First Low-Carbon Ammonia to Europe (Zacks)
09:01AM	Agnico Eagle Divests Stake in Royal Road Minerals for C$5.51M (Zacks)
Oct-03-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Contango ORE, Inc. (CTGO) is a Great Choice (Zacks)
09:15AM	Contango ORE, Inc. (CTGO) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-02-25 09:55AM	Wall Street Analysts Believe Contango ORE, Inc. (CTGO) Could Rally 35.89%: Here's is How to Trade (Zacks)
09:40AM	Are Basic Materials Stocks Lagging Contango ORE, Inc. (CTGO) This Year? (Zacks)
08:00AM	Contango Announces Production of 17,000 ounces of Gold and $33 Million Cash Distribution from Campaign 3-2025 from the Peak Gold JV (PR Newswire)
Sep-26-25 10:07AM	CONTANGO PROVIDES UPDATE ON FINANACING AND EXPLORATION PLANS (PR Newswire)
10:06AM	CONTANGO ORE CLOSES $50 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS (PR Newswire)
Sep-25-25 08:00AM	CONTANGO ORE ANNOUNCES $50 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS (PR Newswire)
Sep-15-25 08:00AM	Contango Announces Inclusion into the Global Junior Gold Miners Index (GDXJ) (PR Newswire) +8.01%
Aug-15-25 03:04PM	Contango Ore Inc (CTGO) Q2 2025 Earnings Call Highlights: A Remarkable Financial Turnaround (GuruFocus.com)
Aug-13-25 11:49PM	Contango (CTGO) Reports Strong Gold Production Results in Q2 2025 (Insider Monkey)
04:30PM	Contango Announces Record High $23.0 Million in Income from Operations and $15.9 Million in Net Income for the Quarter Ended June 30, 2025 (PR Newswire)
07:41AM	Contango Ore Gears Up to Report Q2 Earnings: What to Expect? (Zacks)
Aug-12-25 11:29AM	Undervalued Gold Equities Poised for a Breakout (PR Newswire)
Jul-30-25 08:00AM	Contango Announces Production Results for the Quarter Ended June 30, 2025 (PR Newswire)
Jul-25-25 07:00AM	Bear of the Day: Alpha Metallurgical Resources (AMR) (Zacks)
Jul-18-25 09:40AM	Is Contango ORE, Inc. (CTGO) Stock Outpacing Its Basic Materials Peers This Year? (Zacks)
Jul-17-25 01:11PM	Contango Insider Trim Follows Gold Milestone Amid Modest Confidence Boost (Insider Monkey)
Jul-01-25 09:40AM	Is Contango ORE, Inc. (CTGO) Outperforming Other Basic Materials Stocks This Year? (Zacks)
Jun-25-25 08:30AM	Contango Announces $21.0 Million Cash Distribution from the Peak Gold JV for Production from Campaign #2-2025 (PR Newswire)
Jun-19-25 09:55AM	Does Contango ORE, Inc. (CTGO) Have the Potential to Rally 37.7% as Wall Street Analysts Expect? (Zacks)
Jun-16-25 08:00AM	Contango Announces Production of 15,700 ounces of Gold and Anticipated $20.0 Million Cash Distribution from the Second Peak Gold JV Campaign of 2025 (PR Newswire)
Jun-12-25 09:40AM	Is Cameco (CCJ) Stock Outpacing Its Basic Materials Peers This Year? (Zacks) +5.02%
Jun-10-25 05:30PM	Contango Announces Results of the 2025 Virtual Annual Meeting of Stockholders (PR Newswire)
Jun-09-25 09:55AM	Contango ORE, Inc. (CTGO) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jun-03-25 09:55AM	Wall Street Analysts Predict a 44.7% Upside in Contango ORE, Inc. (CTGO): Here's What You Should Know (Zacks)
May-30-25 12:17AM	Roth Capital Lifted its Price Target for Contango Ore, Inc. (CTGO) (Insider Monkey)
May-27-25 09:08AM	Beat the Market the Zacks Way: GE Aerospace, Monster Beverage, Cencora in Focus (Zacks) +11.80%
May-26-25 09:40AM	Are Basic Materials Stocks Lagging Avino Silver (ASM) This Year? (Zacks)
May-16-25 01:50PM	While Majors Ride Momentum, Smaller Gold Stocks Are Building Something Bigger (PR Newswire)
09:00AM	Contango Ore Inc (CTGO) Q1 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges (GuruFocus.com)
May-14-25 04:15PM	Contango Announces $19.3 Million in Income from Operations for the Quarter Ended March 31, 2025 (PR Newswire) +16.73%
May-13-25 11:15AM	Contango Ore, Inc. (CTGO): A Bull Case Theory (Insider Monkey)
09:49AM	Century Aluminum's Q1 Earnings and Revenues Miss Estimates (Zacks)
07:37AM	Kronos Worldwide's Q1 Earnings Miss Estimates, Sales Beat (Zacks)
07:34AM	Nutrien's Earnings and Revenues Lag Estimates in Q1, Down Y/Y (Zacks)
May-12-25 09:52AM	Chemours' Q1 Earnings Miss Estimates, Revenues Increase Y/Y (Zacks) -6.74%
07:22AM	Kinross' Earnings and Revenues Outpace Estimates in Q1, Up Y/Y (Zacks)
May-09-25 10:30AM	Ingevity Q1 Earnings Up, Revenues Down Y/Y on Repositioning Actions (Zacks)
06:44AM	Cabot's Earnings Surpass Estimates in Q2, Revenues Miss (Zacks)
May-08-25 01:44PM	Westlake's Q1 Earnings and Revenues Miss Estimates, Decline Y/Y (Zacks)
09:40AM	Is Contango ORE, Inc. (CTGO) Stock Outpacing Its Basic Materials Peers This Year? (Zacks)
07:39AM	Barrick Gold's Q1 Earnings Surpass Estimates, Sales Up Y/Y (Zacks)
07:30AM	ArcelorMittal's Earnings and Revenues Surpass Estimates in Q1 (Zacks)
07:14AM	CF Industries' Earnings and Revenues Surpass Estimates in Q1 (Zacks)
07:11AM	Cleveland-Cliffs' Q1 Earnings Miss Estimates, Revenues Beat (Zacks)
May-07-25 11:07AM	Olin Corporation's Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
May-06-25 08:30AM	Contango Announces S-K 1300 Technical Report Summary with Robust Economics and One Year Payback for its Johnson Tract Project (PR Newswire)
Apr-30-25 04:45PM	Contango Provides Corporate Update (PR Newswire)

Contango Silver & Gold, Inc. is an exploration company, which engages in the development and production of gold and silver assets. It includes producing mines, advanced-stage development projects, and exploration properties on low-capex growth and efficient use of existing infrastructure. The company is headquartered in Fairbanks, AK.

CEO & DirectorMr. Rick Van Nieuwenhuyse M.Sc.

CPAMr. J. Michael Clark C.A.

President & DirectorMr. Shawn Khunkhun

Vice President of OperationsMr. Chris Kennedy

Vice President of ExplorationMr. David Larimer

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Van Nieuwenhuyse Rick	President & CEO	Jun 25 '26	Buy	15.24	4,111	62,652	555,251	Jun 26 06:30 PM
Khunkhun Shawn	President and Director	Apr 08 '26	Option Exercise	12.46	20,650	257,299	90,389	Apr 09 06:00 PM
Devine Darren Paul	Director	Apr 08 '26	Option Exercise	12.46	10,325	128,650	49,471	Apr 09 06:00 PM
Nauman Clynton R.	Director	Apr 01 '26	Buy	18.56	10,000	185,600	24,550	Apr 07 05:30 PM
Clark Michael Aaron	CFO & Secretary	Mar 19 '26	Sale	17.92	10,075	180,544	39,798	Mar 20 04:46 PM
Larimer David Gregory	VP Exploration	Mar 19 '26	Sale	17.92	2,775	49,728	12,793	Mar 20 04:30 PM
Van Nieuwenhuyse Rick	President & CEO	Mar 19 '26	Sale	17.92	21,621	387,448	517,140	Mar 20 04:30 PM
Clark Michael Aaron	Officer	Mar 19 '26	Proposed Sale	17.92	10,075	180,537		Mar 19 04:00 PM
Van Nieuwenhuyse Rick	Officer	Mar 19 '26	Proposed Sale	17.92	21,621	387,433		Mar 19 04:00 PM
Clark Michael Aaron	CFO & Secretary	Jan 08 '26	Sale	26.00	10,097	262,522	49,873	Jan 09 06:30 PM
Van Nieuwenhuyse Rick	President & CEO	Jan 08 '26	Sale	26.00	19,608	509,808	538,761	Jan 09 06:00 PM
Clark Michael Aaron	Officer	Jan 08 '26	Proposed Sale	26.00	10,097	262,532		Jan 08 04:32 PM
Van Nieuwenhuyse Rick	Officer	Jan 08 '26	Proposed Sale	26.00	19,608	509,828		Jan 08 04:26 PM
Clark Michael Aaron	CFO & Secretary	Aug 18 '25	Sale	21.66	2,822	61,125	59,970	Aug 18 08:30 PM
Shortz Richard	Director	Aug 18 '25	Sale	21.08	33,150	698,802	84,050	Aug 18 08:00 PM
RICHARD A SHORTZ	Director	Aug 18 '25	Proposed Sale	21.08	33,150	698,842		Aug 18 04:41 PM
Clark Michael Aaron	Officer	Aug 18 '25	Proposed Sale	21.66	2,822	61,121		Aug 18 04:28 PM
Green Darwin	Director	Jul 10 '25	Sale	20.23	1,818	36,778	33,994	Jul 11 05:00 PM

DPC

DPC Holdings PLC

FTH

Faeth Therapeutics Inc

BZUN

Baozun Inc ADR

CTGO

Contango Silver & Gold Inc

Upgrade your Finviz experience